<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373904</url>
  </required_header>
  <id_info>
    <org_study_id>14-03-PATHOLHUM-01</org_study_id>
    <secondary_id>NL49653.072.14</secondary_id>
    <nct_id>NCT02373904</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease</brief_title>
  <official_title>A Prospective, Multi-Center Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlluminOss Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlluminOss Medical, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect safety and performance data of the Photodynamic Bone&#xD;
      Stabilization System (PBSS) when used for the treatment of painful impending and actual&#xD;
      fractures of the humerus secondary to metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Reduction</measure>
    <time_frame>90 days</time_frame>
    <description>VAS Pain Score change of &gt; -33% compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Improvement (Barthel Index of Activities of Daily Living (ADLs) improvement of &gt; +10% from baseline -EORTC QLQ-C30 improvement of &gt; +10% from baseline -EORTC QLQ-BM22 improvement of &gt; +10% from baseline)</measure>
    <time_frame>90 days</time_frame>
    <description>Barthel Index of Activities of Daily Living (ADLs) improvement of &gt; +10% from baseline&#xD;
EORTC QLQ-C30 improvement of &gt; +10% from baseline&#xD;
EORTC QLQ-BM22 improvement of &gt; +10% from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Safety Success (No Serious Device Related Complications -No additional surgical interventions: revisions, supplements, fixations or removals)</measure>
    <time_frame>90 days</time_frame>
    <description>No Serious Device Related Complications&#xD;
No additional surgical interventions: revisions, supplements, fixations or removals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic Safety Success (No device fracture, migrations, mal-alignment or loss of reduction or fixation)</measure>
    <time_frame>90 days</time_frame>
    <description>No device fracture, migrations, mal-alignment or loss of reduction or fixation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Reduction (VAS Pain Score change of &gt; -33% compared to baseline)</measure>
    <time_frame>90, 180 and 360 days</time_frame>
    <description>VAS Pain Score change of &gt; -33% compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Improvement (-Barthel Index of Activities of Daily Living (ADLs) improvement of &gt; +10% from baseline, -EORTC QLQ-C30 improvement of &gt; +10% from baseline -EORTC QLQ-BM22 improvement of &gt; +10% from baseline)</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>Barthel Index of Activities of Daily Living (ADLs) improvement of &gt; +10% from baseline,&#xD;
EORTC QLQ-C30 improvement of &gt; +10% from baseline&#xD;
EORTC QLQ-BM22 improvement of &gt; +10% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Safety Success (No Serious Device Related Complications -No additional surgical interventions: revisions, supplements, fixations or removals)</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>No Serious Device Related Complications&#xD;
No additional surgical interventions: revisions, supplements, fixations or removals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Safety Success (No device fracture, migrations, mal-alignment or loss of reduction or fixation)</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>No device fracture, migrations, mal-alignment or loss of reduction or fixation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of index procedure and length of hospital stay</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability status</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>Determined per Investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of duration of physical therapy prescription</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of prescription and over-the-counter analgesic medication use</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survivability from time of index procedure to death</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and number of AEs</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and number of procedure- and device-related complications</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living score through all follow-up intervals</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>Barthel Index of Activities of Daily Living (ADLs), EORTC QLQ-C30 and EORTC QLQ-BM22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain score from baseline through all follow-up intervals</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>VAS pain scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Humerus Pathological Fracture</condition>
  <arm_group>
    <arm_group_label>Photodynamic Bone Stabilization System (PBSS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photodynamic Bone Stabilization System</intervention_name>
    <description>Treatment of impending and actual pathological fractures of the humerus</description>
    <arm_group_label>Photodynamic Bone Stabilization System (PBSS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -General Inclusion Criteria&#xD;
&#xD;
          1. Skeletally mature adult males and females 18 years of age or older.&#xD;
&#xD;
          2. Impending or actual pathological fracture of the humerus, secondary to metastatic bone&#xD;
             disease.&#xD;
&#xD;
          3. Females: neither pregnant nor intending to become pregnant during the course of the&#xD;
             study, defined as:&#xD;
&#xD;
               1. Postmenopausal for at least 1 year OR&#xD;
&#xD;
               2. Documented oophorectomy or hysterectomy&#xD;
&#xD;
               3. Surgically sterile OR&#xD;
&#xD;
               4. If of childbearing potential, must be practicing double-barrier method of birth&#xD;
                  control, be willing to avoid pregnancy for the period of study participation and&#xD;
                  have a negative pregnancy test at screening&#xD;
&#xD;
          4. Able to understand and provide informed consent.&#xD;
&#xD;
          5. Willing and able to comply with post-operative treatment protocol and follow-up visit&#xD;
             schedule.&#xD;
&#xD;
             -Impending Fracture-Specific Inclusion Criteria&#xD;
&#xD;
          6. Documented presence of solitary metastatic lesion.&#xD;
&#xD;
          7. Mirels Criteria Score ≥ 8.&#xD;
&#xD;
          8. Destruction of cortical bone at impending fracture site &gt; 50%.&#xD;
&#xD;
             -Actual Fracture-Specific Inclusion Criteria&#xD;
&#xD;
          9. Radiograph-confirmed diagnosis of acute, single isolated fracture of the humerus. AO&#xD;
             classification 11A1, 11A2 and 11B1, 11B2 and 12A1,12A2 and 12B1, 12B2 and 13A1,13A2&#xD;
             and 13B1, 13B2.&#xD;
&#xD;
         10. Fracture is closed, Gustilo Type I or IIA.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -General Exclusion Criteria&#xD;
&#xD;
          1. Primary tumor (osteogenic origin, etc.) at site.&#xD;
&#xD;
          2. Impending fracture or actual fracture location other than humerus.&#xD;
&#xD;
          3. Current concomitant traumatic fracture of any other location.&#xD;
&#xD;
          4. Active or incompletely treated infections that could involve the device implant site.&#xD;
&#xD;
          5. Distant foci of infection that may spread to the implant site.&#xD;
&#xD;
          6. Allergy to implant materials or dental glue.&#xD;
&#xD;
          7. Vascular insufficiency, muscular atrophy, or neuromuscular disease at implant site.&#xD;
&#xD;
          8. Uncooperative patients, or patients who are incapable of following directions (for&#xD;
             example, as a consequence of a neurological or psychiatric disorder).&#xD;
&#xD;
             -Impending Fracture-Specific Exclusion Criteria&#xD;
&#xD;
          9. Mirels Score &lt; 8.&#xD;
&#xD;
         10. Destruction of cortical bone at impending fracture site &lt; 50%.&#xD;
&#xD;
         11. Prior surgery and/or prior fracture of affected site.&#xD;
&#xD;
         12. Any articular component to impending fracture site.&#xD;
&#xD;
             -Actual Fracture-Specific Exclusion Criteria&#xD;
&#xD;
         13. Index treatment is greater than 28 days post fracture.&#xD;
&#xD;
         14. Open fractures with severe contamination.&#xD;
&#xD;
         15. Extremely comminuted fractures where insufficient holding power of the balloon on the&#xD;
             intramedullary canal is probable.&#xD;
&#xD;
         16. Delivery sheath is unable to cross fracture site after proper fracture reduction and&#xD;
             realignment&#xD;
&#xD;
         17. Patients whose intramedullary canal at site of fracture measures smaller than the&#xD;
             diameter of the sheath provided.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vinzenz-Hospital GmbH</name>
      <address>
        <city>Koln</city>
        <zip>D-50733</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahn-Dill Kliniken</name>
      <address>
        <city>Wetzlar</city>
        <zip>35578</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Spontaneous</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 15, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 5, 2018</submitted>
    <returned>October 8, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

